#1 Clinical Trials Search in Europe

Emactuzumab

Emactuzumab is an investigational drug being studied in clinical trials for the treatment of various types of cancer, including tenosynovial giant cell tumor (TGCT), solid tumors, and non-Hodgkin lymphoma. This article will explore the ongoing research on emactuzumab, its potential benefits, and its use in combination with other cancer therapies.

Table of Contents

What is Emactuzumab?

Emactuzumab is an investigational drug being studied for its potential in treating various types of cancer[2]. It belongs to a class of medications known as immunotherapy drugs, which work by helping the body’s immune system fight cancer cells[3]. Emactuzumab is also known by its alternative name RO5509554[4].

How Does Emactuzumab Work?

Emactuzumab targets a specific type of immune cell called tumor-associated macrophages (TAMs)[3]. These are cells that can sometimes help cancer grow and spread. By targeting these cells, emactuzumab aims to reduce their numbers and potentially slow down or stop cancer growth. It’s part of a broader strategy to enhance the body’s natural defenses against cancer.

Conditions Treated with Emactuzumab

Emactuzumab is being investigated for use in several types of cancer:

  • Tenosynovial Giant Cell Tumor (TGCT): This is a rare type of tumor that affects the tissues around joints[1].
  • Advanced Solid Tumors: These are cancers that form solid masses in the body, such as breast, lung, or colon cancer[2].
  • Non-Hodgkin Lymphoma: This is a type of cancer that starts in white blood cells called lymphocytes[4].

Clinical Trials and Research

Emactuzumab is currently being studied in several clinical trials:

  • A Phase III study for TGCT where surgical removal is not an option[1].
  • A Phase Ib study combining emactuzumab with another immunotherapy drug called atezolizumab for advanced solid tumors[2].
  • A Phase Ib study investigating emactuzumab with RO7009789 (another experimental drug) for advanced solid tumors[3].
  • A study combining emactuzumab with atezolizumab and obinutuzumab for non-Hodgkin lymphoma[4].

These trials aim to determine the safety and effectiveness of emactuzumab, either alone or in combination with other drugs.

How is Emactuzumab Administered?

Emactuzumab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosage and frequency can vary depending on the specific trial and condition being treated. For example:

  • In some trials, it’s given every 3 weeks at a dose of 1000 mg[4].
  • In others, it may be given every 2 weeks for a total of 5 times, followed by an observation period[1].

The exact schedule and dosage would be determined by your healthcare team based on your specific situation and the treatment protocol.

Potential Side Effects

As emactuzumab is still in clinical trials, all of its potential side effects are not yet fully known. However, researchers are closely monitoring for any adverse events during these studies[2]. Common side effects of immunotherapy drugs can include fatigue, skin reactions, and flu-like symptoms. More serious side effects are possible but less common. It’s important to discuss potential risks with your healthcare provider if you’re considering participating in a clinical trial.

Future Prospects

Emactuzumab shows promise in treating various types of cancer, particularly when combined with other immunotherapy drugs. Ongoing research aims to determine its effectiveness and safety profile. If successful in clinical trials, emactuzumab could potentially become an important tool in cancer treatment, especially for patients with limited options[1][2].

It’s important to note that as an investigational drug, emactuzumab is not yet approved for general use outside of clinical trials. Patients interested in this treatment should discuss with their oncologist about the possibility of participating in relevant clinical trials.

Aspect Details
Drug Name Emactuzumab
Type of Drug Investigational immunotherapy agent
Conditions Studied Tenosynovial Giant Cell Tumor (TGCT), Advanced Solid Tumors, Non-Hodgkin Lymphoma
Administration Intravenous (IV) infusion
Dosage Varies by trial (e.g., 500 mg, 1000 mg)
Combination Therapies Atezolizumab, Obinutuzumab, RO7009789
Trial Phases Phase 1b, Phase 3
Primary Outcomes Safety, Efficacy, Overall Response Rate
Secondary Outcomes Pharmacokinetics, Duration of Response, Progression-Free Survival

FAQ

  • What is emactuzumab? Emactuzumab is an investigational drug being studied for the treatment of various types of cancer. It is designed to target specific cells in the immune system to help fight cancer.
  • What types of cancer is emactuzumab being studied for? Emactuzumab is being investigated for the treatment of tenosynovial giant cell tumor (TGCT), advanced solid tumors, and non-Hodgkin lymphoma.
  • How is emactuzumab administered? Emactuzumab is typically administered as an intravenous (IV) infusion. The dosage and frequency may vary depending on the specific clinical trial and the condition being treated.
  • Is emactuzumab used alone or in combination with other drugs? Emactuzumab is being studied both as a single agent and in combination with other cancer therapies, such as atezolizumab, obinutuzumab, and RO7009789.
  • What are the potential side effects of emactuzumab? As with any investigational drug, the full range of side effects is still being studied. Clinical trials are designed to monitor and assess the safety of emactuzumab, including any adverse events that may occur during treatment.

Ongoing Clinical Trials on Emactuzumab

  • Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Italy The Netherlands Poland +2

Glossary

  • Tenosynovial Giant Cell Tumor (TGCT): A rare, non-cancerous tumor that affects the soft tissue lining of joints and tendons.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Solid Tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Non-Hodgkin Lymphoma: A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • Atezolizumab: An immunotherapy drug used to treat certain types of cancer by helping the immune system fight cancer cells.
  • Obinutuzumab: A monoclonal antibody used to treat certain types of blood cancers, including some forms of non-Hodgkin lymphoma.
  • Placebo: An inactive substance that looks like a medication but contains no active drug ingredients.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. https://clinicaltrials.eu/trial/study-on-emactuzumab-for-patients-with-tenosynovial-giant-cell-tumor/
  2. https://clinicaltrials.gov/study/NCT02323191
  3. https://clinicaltrials.gov/study/NCT02760797
  4. https://clinicaltrials.gov/study/NCT03369964